Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 7:11:4.
doi: 10.1186/s12993-014-0048-2.

Reduced levels of plasma polyunsaturated fatty acids and serum carnitine in autistic children: relation to gastrointestinal manifestations

Reduced levels of plasma polyunsaturated fatty acids and serum carnitine in autistic children: relation to gastrointestinal manifestations

Gehan A Mostafa et al. Behav Brain Funct. .

Abstract

Background: Gastrointestinal (GI) manifestations are common in autistic children. Polyunsaturated fatty acids (PUFAs) and carnitine are anti-inflammatory molecules and their deficiency may result in GI inflammation. The relationship between the increased frequency of GI manifestations and reduced levels of PUFAs and carnitine was not previously investigated in autistic patients. This study was the first to investigate plasma levels of PUFAs and serum carnitine in relation to GI manifestations in autistic children.

Methods: Plasma levels of PUFAs (including linoleic, alphalinolenic, arachidonic "AA" and docosahexaenoic "DHA" acids) and serum carnitine were measured in 100 autistic children and 100 healthy-matched children.

Results: Reduced levels of serum carnitine and plasma DHA, AA, linolenic and linoleic acids were found in 66%, 62%, 60%, 43% and 38%, respectively of autistic children. On the other hand, 54% of autistic patients had elevated ω6/ω3 ratio. Autistic patients with GI manifestations (48%) had significantly decreased levels of serum carnitine and plasma DHA than patients without such manifestations. In addition, autistic patients with GI manifestations had significantly increased percentage of reduced serum carnitine (91.7%) and plasma DHA levels (87.5%) than patients without such manifestations (42.3% and 38.5%, respectively), (P < 0.001 and P < 0.001%, respectively).

Conclusions: Reduced levels of plasma DHA and serum carnitine levels may be associated with the GI problems in some autistic patients. However, this is an initial report, studies are recommended to invesigate whether reduced levels of carnitine and DHA are a mere association or have a pathogenic role in GI problems in autistic patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Geier DA, Kern JK, Davis G, King PG, Adams JB, Young JL, et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit. 2011;17:I15–I123. doi: 10.12659/MSM.881792. - DOI - PMC - PubMed
    1. Legido A, Jethva R, Goldenthal MJ. Mitochondrial dysfunction in autism. Semin Pediatr Neurol. 2013;20(3):163–175. doi: 10.1016/j.spen.2013.10.008. - DOI - PubMed
    1. Burlingame B, Nishida C, Uauy R, Weisell R. Fats and fatty acids in human nutrition: introduction. Ann Nutr Metab. 2009;55:5–7. doi: 10.1159/000228993. - DOI - PubMed
    1. Park JM, Kwon SH, Han YM, Hahm KB, Kim EH. Omega-3 polyunsaturated Fatty acids as potential chemopreventive agent for gastrointestinal cancer. J Cancer Prev. 2013;18(3):201–208. doi: 10.15430/JCP.2013.18.3.201. - DOI - PMC - PubMed
    1. Innis SM. The role of dietary n-6 and n-3 fatty acids in the developing brain. Dev Neurosci. 2000;22:474–480. doi: 10.1159/000017478. - DOI - PubMed

Publication types

LinkOut - more resources